ImmunoCellular Therapeutics, Ltd.
(NYSE Amex Equities : IMUC)

( )
IMUC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Loading IMUC News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.80%69.291.0%$931.38m
AMGNAmgen Inc.
-0.09%173.140.8%$656.50m
BIIBBiogen Inc.
-0.71%286.900.9%$536.61m
CELGCelgene Corporation
-1.42%119.441.0%$479.99m
REGNRegeneron Pharmaceuticals, Inc.
0.12%371.611.9%$348.38m
ALXNAlexion Pharmaceuticals, Inc.
0.83%129.892.0%$299.57m
TSROTESARO, Inc.
-0.05%190.2715.3%$198.98m
INCYIncyte Corporation
1.55%122.362.3%$170.12m
ILMNIllumina, Inc.
-0.75%162.153.9%$148.02m
VRTXVertex Pharmaceuticals Incorporated
-2.02%86.552.6%$140.07m
CLVSClovis Oncology, Inc.
-4.27%62.9916.4%$132.37m
EXELExelixis, Inc.
-0.04%23.115.5%$131.47m
AAgilent Technologies, Inc.
-0.54%51.351.7%$117.26m
ACADACADIA Pharmaceuticals Inc.
-0.20%39.2019.0%$93.83m
BMRNBioMarin Pharmaceutical Inc.
0.41%90.244.0%$89.98m

Company Profile

ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. Its lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 31, 2006 and is headquartered in Calabasas, CA.